Striatal GDNF Neurons Chemoattract RET-Positive Dopamine Axons at Seven Times Farther Distance Than Medium Spiny Neurons
Cells · 2024
DOI: 10.3390/cells13121059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Ana Rosa Montaño-Rodriguez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland. Hauptthemen laut MEDLINE: Glial Cell Line-Derived Neurotrophic Factor, Axons, Corpus Striatum, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, ERA-NET NEURON, Swedish Research Council.
Abstract (Originalsprache)
Glial cell line-derived neurotrophic factor (GDNF) is among the strongest dopamine neuron function- and survival-promoting factors known. Due to this reason, it has clinical relevance in dopamine disorders such as Parkinson’s disease and schizophrenia. In the striatum, GDNF is exclusively expressed in interneurons, which make up only about 0.6% of striatal cells. Despite clinical significance, histological analysis of striatal GDNF system arborization and relevance to incoming dopamine axons, which bear its receptor RET, has remained enigmatic. This is mainly due to the lack of antibodies able to visualize GDNF- and RET-positive cellular processes; here, we overcome this problem by using knock-in marker alleles. We find that GDNF neurons chemoattract RET+ axons at least seven times farther in distance than medium spiny neurons (MSNs), which make up 95% of striatal neurons. Furthermore, we provide evidence that tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, is enriched towards GDNF neurons in the dopamine axons. Finally, we find that GDNF neuron arborizations occupy approximately only twelve times less striatal volume than 135 times more abundant MSNs. Collectively, our results improve our understanding of how endogenous GDNF affects striatal dopamine system function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland.
- Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, 17177 Stockholm, Sweden.
ORCID-Profile: Ana Rosa Montaño-Rodriguez, Jaan-Olle Andressoo
Förderung
- Academy of Finland
- ERA-NET NEURON
- Swedish Research Council
- European Research Council
- Sigrid Juselius Foundation
- Center of Innovative Medicine (CIMED)
- Hjärnfonden, Swedish Research Council
- Helsinki Institute of Life Science
Zitieren
APA
Montaño-Rodriguez, A. R., Schorling, T., & Andressoo, J. O. (2024). Striatal GDNF Neurons Chemoattract RET-Positive Dopamine Axons at Seven Times Farther Distance Than Medium Spiny Neurons. Cells. https://doi.org/10.3390/cells13121059
Vancouver
Montaño-Rodriguez AR, Schorling T, Andressoo JO. Striatal GDNF Neurons Chemoattract RET-Positive Dopamine Axons at Seven Times Farther Distance Than Medium Spiny Neurons. Cells. 2024. doi:10.3390/cells13121059
BibTeX
@article{MontaoRodriguez2024,
author = {Montaño-Rodriguez, Ana Rosa and Schorling, Tabea and Andressoo, Jaan-Olle},
title = {Striatal GDNF Neurons Chemoattract RET-Positive Dopamine Axons at Seven Times Farther Distance Than Medium Spiny Neurons},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13121059}
}
EUVIMED